DXCM
Dexcom
Earnings and EPS analysis
- Stocks
- Healthcare
- NASDAQ: DXCM
- Earnings
EPS in 2026 (TTM): $2.4
Last Report Period Date: Mar 31, 2026
Currently, DXCM's trailing twelve months (TTM) EPS stands at $2.4, according to the most recent financial reports. Dexcom's earnings per share in 2025 came in at $2.14, marking an increase from $1.46 in 2024. DXCM recorded an EPS of $0.52 for the quarterly period ending on Mar 31, 2026.
DXCM earnings history
In 2025, Dexcom's EPS was $2.14, an increase of 46.6% from $1.46 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was $0.52, marking a 92.6% increase compared to the same quarter last year. DXCM's TTM EPS is $2.4 as of March 2026. Dexcom's EPS for 2024 was $1.46, a 4.3% rise from 2023.
DXCM earnings chart
DXCM EPS growth history
Over the past 12 months, Dexcom has recorded an earnings per share growth of 92.6% (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS annual growth rate of 34.5% per year for the last 3 years. Over the last five years, the company had an average annual EPS growth of 7.9%.
DXCM Earnings Waterfall
DXCM Earnings vs Peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| MDT Medtronic plc | 21.5 | 3.3% | 9.8% | 6.9% |
| ABT Abbott Laboratories | 25.19 | -51.4% | -1.8% | 8.2% |
| JNJ Johnson & Johnson | 27.39 | 90.6% | 17.7% | 14.8% |
| DXCM Dexcom Inc | 28.7 | 46.6% | 34.5% | 7.9% |
| BDX Becton Dickinson & Co | 36.45 | -0.9% | -0.6% | 16.2% |
| WST West Pharmaceutical Services Inc | 44.72 | 1.2% | -4.6% | 7.9% |
| EW Edwards Lifesciences Corp | 46.02 | -73.6% | -9.2% | 6.9% |
| TNDM Tandem Diabetes Care Inc | N/A | -106.8% | N/A | N/A |
| QDEL Quidel Corp | N/A | 45.4% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.